- CMTA Appoints David Skarinsky to its Therapy Expert Board
The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth disease (CMT) research that’s aimed at bringing treatments and a cure to patients of this rare disease, is pleased to announce the appointment of David Skarinsky to its Strategy to ...Read more ... - NMD Pharma Receives FDA Approval to Initiate Phase II Clinical Trial of NMD670 in CMT PatientsThe Charcot-Marie-Tooth Association (CMTA) is excited to share that our Alliance Partner, NMD Pharma, has received clearance from the US Food and Drug Administration (FDA) to initiate a Phase II clinical trial for their investigational drug, NMD670, in patients with ...Read more ...
- CMTA’s $240K Investment Targets Gene Replacement Therapy in CMT4 SubtypesThe Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth (CMT) disease research aimed at bringing treatments to patients, announced today an investment of $240K into a new gene replacement therapy for CMT4A, with a potential to translate to other ...Read more ...
- From Gene Discovery to Gene Editing: Closing the Diagnostic Gap and Developing CRISPR/Cas9 Capabilities in CMTFinding Your Gene Researchers have discovered over 120 genes linked to CMT; dozens were found with CMTA funding initiatives. Despite this, referred to as the “diagnostic gap,” more than 50% of all who have CMT Type 2 still aren’t able to ...Read more ...
- 2024 CMTA Patient & Research Summit Registration is Now OpenThe 2024 CMTA Patient & Research Summit will take place on Friday, September 6th – Sunday, September 8th at the Denver Marriott West in Denver, Colorado. The CMTA Summit will offer life-improving presentations on living well with CMT and will ...Read more ...
Your legacy can help bring an end to CMT. Learn how a planned gift can make an impact for generations to come.
